The future of ulcerative colitis (UC) treatment is likely to include new therapies for those who don't respond to conventional treatments.
One promising future treatment option is tulisokibart, a monoclonal antibody. A phase 2 trial, announced on 25-Sept-2024, showed encouraging results for tulisokibart in patients with moderate-to-severe UC who have not responded to conventional inflammatory bowel disease (IBD) treatments.
In summary, while not a definitive cure, tulisokibart represents a significant advancement and a potential future treatment option for individuals struggling with ulcerative colitis that is resistant to current therapies.
